Cramer Says Pfizer (PFE) Should Buy Allergan (AGN)
More News related to AGN
- THE Aesthetic Academy Debuts in Beverly Hills
- Allergan (AGN) March put volatility flat at 34
- Allergan (AGN) Shares Jump Higher as Cowen Issues Intraday Upgrade
- Allergan (AGN) Reports Inline Q4 Adj-EPS of $0.78; Guides Q1, FY10
- Allergan Reports Fourth Quarter 2009 Operating Results
More News related to MNT
- Allergan (AGN) Up On Takeover Rumors
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Johnson & Johnson (JNJ) Completes Tender Offer of Mentor Corp (MNT)
- Johnson & Johnson (JNJ) Receives Clearance for Tender to Buy Mentor; Sees Deal Dilutive to '09 EPS by $0.03-$0.05
- S&P Announces Changes to US Indices: LSTR for PSUN, ASEI for LSTR, BLUD for FBN, AVAV for BLUD, BRLI for MNT
More News related to PFE
- Active equity option families in first 30 minutes: PFE, BAC, CSCO, AMZN, AAPL
- Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness
- Top 10 News Items 2/1-2/5: 9.7% Unemployment Rate Surprises the Market, Dow Breaks 10,000, But Recovers, Troubles at Toyota Continue
- Active equity option families in first 30 minutes: BAC F PFE AAPL
- QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
More News related to Insiders' Blog
- Sprint (S): Q4 Earnings Preview
- NYSE Euronext (NYX) Beats the Street's Q4 Views on Both the Top and Bottom Lines
- Q1 Earnings Preview: Walt Disney (DIS)
- S&P Revises Credit Outlooks On BofA (BAC) and Citi (C) to Negative, Saying No More Free Govenment Handouts
- Airline Stocks Taking-Off as UAL Reports Strong Monthly Traffic Results; Investors Shrug at Flight Delays (UAUA, DAL, LUV, AMR, more)
On Mad Money tonight, Jim Cramer said Pfizer (NYSE: PFE) should really take a strong look at buying Allergan (NYSE: AGN). Cramer thinks this is a smart play similar to Johnson & Johnson buying out Mentor Corporation (NYSE: MNT) earlier in the week.
Both Allergan and Mentor produce products that are used in cosmetic surgeries.
Additionally, Cramer liked that Allergan has a strong growth rate, whereas Pfizer has no growth. Therefore, if Pfizer makes a play for Allergan, it would get that much needed growth the Street covets.
In today's trading, Allergan closed at $36.20 and currently in the after-hours it is at $35.18.
Allergan, Inc. is a multi-specialty healthcare company focused on developing and commercializing pharmaceuticals, biologics and medical devices.
Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News!
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
+0.58Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
